Work

Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance

Year: 2019

Type: review

Source: Oncogene

DOI: 10.1038/s41388-019-0870-y

Authors: Stacie K. Totsch, Charles Schlappi, Kyung-Don Kang, Andrew S. Ishizuka, Geoffrey M. Lynn, Brandon Fox, Elizabeth A. Beierle, Richard J. Whitley, James M. Markert, G. Yancey Gillespie, Joshua D. Bernstock, Gregory K. Friedman

Institutions: University of Alabama at Birmingham, UAB Medicine, Avidea Technologies (United States), Brigham and Women's Hospital, Harvard University

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Defense, U.S. Department of Health and Human Services, American Brain Tumor Association, Rally Foundation, Hyundai Motor Group, National Institutes of Health, U.S. Food and Drug Administration, National Cancer Institute, National Institute of General Medical Sciences, Hyundai Hope On Wheels, Kaul Pediatric Research Institute

Awards: G1336880266, Medical Scientist Training Program, Research Training Program in Basic and Translational Oncology, A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma., G3763226385, G4370540960, G5076538404, INTRAVENTRICULAR DELIVERY OF ENGINEERED ONCOLYTIC HERPES SIMPLEX VIROTHERAPY TO TREAT LOCALIZED AND METASTATIC PEDIATRIC BRAIN TUMORS

OpenAlex ID: W2957488658

FWCI: 1.325

Cites: 108

Cited by: 68

Related to: 10